Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Shengke Pharmaceuticals (Jiangsu) Ltd. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 2 distinct examiners, reflecting a distributed prosecution strategy across the company's current filings. The portfolio's activity is situated within 2 distinct art units, which suggests the underlying technology is diverse in its technical classification within the pharmaceutical sector.
Jackson J Hernandez is the busiest examiner for the company, currently overseeing 1 pending office action. This specific workload accounts for 1 of the 2 total pending actions for the portfolio. With 2 examiners and 2 art units involved, the prosecution process is spread across multiple patent office divisions. Practitioners should focus on the specific requirements of these different units, as their individual decisions will define the immediate success of the company's intellectual property efforts. This distribution requires a coordinated approach to ensure consistency across the 2 pending matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HERNANDEZ, JACKSON J | 1 | 50.7% | +39.2% |
| WILSON, JERICA KATLYNN | 1 | 60.5% | +39.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18023035 | 1H-IMIDAZO [4,5-H] QUINAZOLINE COMPOUND AS NOVEL SELECTIVE FLT3 INHIBITORS | HERNANDEZ, JACKSON J | 15d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18023035 | 1H-IMIDAZO [4,5-H] QUINAZOLINE COMPOUND AS NOVEL SELECTIVE FLT3 INHIBITORS | HERNANDEZ, JACKSON J | 15d |
| 17791665 | NOVEL COMPOUNDS AS INHIBITORS OF PCSK9 | WILSON, JERICA KATLYNN | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18023035 | 1H-IMIDAZO [4,5-H] QUINAZOLINE COMPOUND AS NOVEL SELECTIVE FLT3 INHIBITORS | HERNANDEZ, JACKSON J | 1627 | §103§112Other | Final Rejection | 15d | Pending | Feb 24, 2023 |
| 17791665 | NOVEL COMPOUNDS AS INHIBITORS OF PCSK9 | WILSON, JERICA KATLYNN | 1621 | §112DP | Non-Final OA | — | Pending | Jul 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShengke Pharmaceuticals (Jiangsu) Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Jackson J Hernandez has the most, with 1 of Shengke Pharmaceuticals (Jiangsu) Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
